Literature DB >> 33224813

Permanent postoperative hypoparathyroidism: an analysis of prevalence and predictive factors for adequacy of control in a cohort of 260 patients.

Juan J Díez1,2, Emma Anda3, Julia Sastre4, Begoña Pérez Corral5, Cristina Álvarez-Escolá6, Laura Manjón7, Miguel Paja8, Marcel Sambo9, Piedad Santiago Fernández10,11, Concepción Blanco Carrera12, Juan C Galofré13, Elena Navarro14, Carles Zafón15, Eva Sanz15, Amelia Oleaga8, Orosia Bandrés16, Sergio Donnay17, Ana Megía18, María Picallo9, Cecilia Sánchez Ragnarsson7, Gloria Baena-Nieto19, José Carlos Fernández-García20, Beatriz Lecumberri6, Manel Sahún de la Vega21, Ana R Romero-Lluch14, Pedro Iglesias1,2.   

Abstract

BACKGROUND: Recent guidelines for the treatment of hypoparathyroidism emphasize the need for long-term disease control, avoiding symptoms and hypocalcaemia. Our aim has been to analyze the prevalence of poor disease control in a national cohort of patients with hypoparathyroidism, as well as to evaluate predictive variables of inadequate disease control.
METHODS: From a nation-wide observational study including a cohort of 1792 patients undergoing total thyroidectomy, we selected 260 subjects [207 women and 53 men, aged (mean ± SD) 47.2±14.8 years] diagnosed with permanent hypoparathyroidism. In every patient demographic data and details on surgical procedure, histopathology, calcium (Ca) metabolism, and therapy with Ca and calcitriol were retrospectively collected. A patient was considered not adequately controlled (NAC) if presented symptoms of hypocalcemia or biochemical data showing low serum Ca levels or high urinary Ca excretion.
RESULTS: Two hundred and twenty-one (85.0%) patients were adequately controlled (AC) and 39 (15.0%) were NAC. Comparison between AC and NAC patients did not show any significant difference in demographic, surgical, and pathological features. Rate of hospitalization during follow-up was significantly higher among NAC patients in comparison with AC patients (35.9% vs. 10.9%, P<0.001). Dose of oral Ca and calcitriol were also significantly higher in NAC subjects. In a subgroup of 129 patients with serum parathyroid hormone (PTH) levels available, we found that NAC patients exhibited significantly lower postoperative PTH concentrations than AC patients [median (interquartile range) 3 (1.9-7.8) vs. 6.9 (3.0-11) pg/mL; P=0.009].
CONCLUSIONS: In a nation-wide cohort of 260 subjects with definitive hypoparathyroidism, 15% of them had poor disease control. These patients required higher doses of oral Ca and calcitriol, had higher rate of hospitalization during follow-up and showed lower PTH concentrations in the postoperative period. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Permanent hypoparathyroidism; adequacy of control; parathyroid hormone (PTH); thyroidectomy

Year:  2020        PMID: 33224813      PMCID: PMC7667118          DOI: 10.21037/gs-20-288

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  31 in total

1.  HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy.

Authors:  Gemma Marcucci; Luisella Cianferotti; Simone Parri; Paola Altieri; Emanuela Arvat; Salvatore Benvenga; Corrado Betterle; Marta Bondanelli; Marco Boscaro; Valentina Camozzi; Grazia Maria Centaro; Filomena Cetani; Iacopo Chiodini; Anna Ciampolillo; Annamaria Colao; Sabrina Corbetta; Maria Laura De Feo; Ettore Degli Uberti; Antongiulio Faggiano; Rachele Fornari; Achille Lucio Gaspari; Francesco Giorgino; Valeria Giuliani; Maurizio Iacobone; Nadia Innaro; Olga Lamacchia; Andrea Lenzi; Giovanna Mantovani; Claudio Marcocci; Laura Masi; Silvia Migliaccio; Serena Palmieri; Renato Pasquali; Giuliano Perigli; Valentina Piccini; Elisabetta Romagnoli; Rosaria Maddalena Ruggeri; Francesco Rulli; Maria Teresa Samà; Giuseppe Tomaino; Francesco Trimarchi; Maria Chiara Zatelli; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2018-03-06       Impact factor: 4.333

2.  Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer.

Authors:  Se Hyun Paek; Young Mi Lee; Sun Young Min; Seok Won Kim; Ki Wook Chung; Yeo Kyu Youn
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

3.  Outcome of protracted hypoparathyroidism after total thyroidectomy.

Authors:  A Sitges-Serra; S Ruiz; M Girvent; H Manjón; J P Dueñas; J J Sancho
Journal:  Br J Surg       Date:  2010-11       Impact factor: 6.939

4.  Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study.

Authors:  Line Underbjerg; Tanja Sikjaer; Lars Rejnmark
Journal:  J Bone Miner Res       Date:  2018-02-14       Impact factor: 6.741

5.  Prediction of permanent hypoparathyroidism after total thyroidectomy.

Authors:  M Almquist; P Hallgrimsson; E Nordenström; A Bergenfelz
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

6.  Mortality in patients with permanent hypoparathyroidism after total thyroidectomy.

Authors:  M Almquist; K Ivarsson; E Nordenström; A Bergenfelz
Journal:  Br J Surg       Date:  2018-04-17       Impact factor: 6.939

7.  Kinetics of serum parathyroid hormone during and after thyroid surgery.

Authors:  M Hermann; J Ott; R Promberger; F Kober; M Karik; M Freissmuth
Journal:  Br J Surg       Date:  2008-12       Impact factor: 6.939

8.  The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study.

Authors:  Line Underbjerg; Tanja Sikjaer; Leif Mosekilde; Lars Rejnmark
Journal:  J Bone Miner Res       Date:  2015-05-31       Impact factor: 6.741

9.  A nomogram to predict the likelihood of permanent hypoparathyroidism after total thyroidectomy based on delayed serum calcium and iPTH measurements.

Authors:  Antonio Sitges-Serra; Joaquín Gómez; Marcin Barczynski; Leyre Lorente-Poch; Maurizio Iacobone; Juan Sancho
Journal:  Gland Surg       Date:  2017-12

10.  Correlation between iPTH Levels on the First Postoperative Day After Total Thyroidectomy and Permanent Hypoparathyroidism: Our Experience.

Authors:  Gian Luigi Canu; Fabio Medas; Alessandro Longheu; Francesco Boi; Giovanni Docimo; Enrico Erdas; Pietro Giorgio Calò
Journal:  Open Med (Wars)       Date:  2019-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.